A recombinant enzyme that enhances the activity of the body’s natural antithrombotic, thrombolytic and cytoprotective defense systems. AB002 is in phase 1 clinical trial stage of development for use in acute cardiovascular events and other indications.
A recombinant monoclonal antibody that selectively inhibits the activation of coagulation factor IX (F9) by coagulation factor XI (F11). AB012 is in late pre-clinical development with a partner company for use as a safe antithrombotic agent.
A recombinant monoclonal antibody that selectively inhibits assembly of the blood contact activation complex. AB023 is in phase 2 clinical trial stage of development. Intended indications for AB023 include long, medium, or short-term use in a broad range of cardiovascular, hematological, infectious, and neurological indications.
A recombinant monoclonal antibody that selectively inhibits the activity of the contact activation enzyme of blood. AB054 is in pre-clinical development stage for acute and short-term use during extracorporeal organ support, severe infections, and select severe allergies.
An antisense oligonucleotide that reduces the synthesis of a cytokine hormone. AB062 is in early pre-clinical development for multiple indications.